ArticleJournal of acquired immune deficiency syndromes (1999)2025
Factors Associated With Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda.
Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundTenofovir/lamivudine/dolutegravir (TLD) is now the most prescribed antiretroviral therapy (ART) regimen worldwide. Although effective and well-tolerated, dolutegravir has been associated with weight gain and neuropsychiatric symptoms. The relationship between these adverse effects and adherence to TLD has not been well characterized.
methodsWe conducted a secondary analysis of a prospective cohort study that followed 675 adults with HIV for 48 weeks in southwestern Uganda after they either transitioned to TLD from older ART regimens or newly initiated ART with TLD. At study weeks 0, 24, and 48, participants completed questionnaires assessing self-reported adherence, use of non-HIV medications, and symptoms. Clinical parameters related to HIV and opportunistic infections were obtained by chart review. Generalized estimating equation logistic regression models were fit to assess factors associated with incomplete adherence.
resultsIn total, 642 participants (95.1%; median age 44 years; 45.6% female) contributed data for at least two study visits. Incomplete adherence to TLD was rare overall, reported by 54 participants (8.4%) through 48 weeks. Incident headaches were associated with incomplete adherence (aOR 1.68; 95% CI: 1.03 to 2.76; P = 0.04), whereas previous ART experience (aOR 0.38; 95% CI: 0.21 to 0.70; P ≤ 0.01) and prescription of ≥1 non-HIV medication (aOR 0.48; 95% CI: 0.29 to 0.79; P ≤ 0.01) predicted better adherence. We found no relationship between perceived weight gain and incomplete adherence (aOR 0.39; 95% CI: 0.11 to 1.39; P = 0.15).
conclusionsIncident headaches were associated with incomplete adherence to TLD in southwestern Uganda, whereas established pill-taking routines were associated with better adherence. Dolutegravir-associated weight gain did not affect adherence in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.